预约演示
更新于：2026-01-29
Chloral Hydrate
水合氯醛
更新于：2026-01-29
概要
基本信息
原研机构- |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C2H3Cl3O2 |
InChIKeyRNFNDJAIBTYOQL-UHFFFAOYSA-N |
CAS号302-17-0 |
关联
52
项与 水合氯醛 相关的临床试验CTR20253105
SH081012口服用浓溶液在中国健康受试者中单中心、开放、随机、单剂量、交叉的药代动力学比较研究
NCT06606899
A Comparative Study Between Efficacy of Combined Oral Melatonin With Nasal Sevoflurane Versus Combined Oral Chloral Hydrate With Nasal Sevoflurane in Sedation of Pre-school Children Undergoing Brain Magnetic Resonance Imaging
ChiCTR2400088869
Sedative effect of intranasal dexmedetomidine combined with chloral hydrate in children undergoing echocardiography
100 项与 水合氯醛 相关的临床结果
登录后查看更多信息
100 项与 水合氯醛 相关的转化医学
登录后查看更多信息
100 项与 水合氯醛 相关的专利（医药）
登录后查看更多信息
3,213
项与 水合氯醛 相关的文献（医药）2026-01-01BMJ Open
Midazolam oral solution for neonatal MRI: study protocol of a randomised controlled trial
Article
作者: Lu, Zhuo ; Song, Ting ; Xu, Li ; Wang, Hao ; Cheng, Zhangqin ; Cui, Yu
Introduction:
Current medications used for neonatal MRI sedation may lead to complications such as decreased oxygen saturation, apnoea and bradycardia. There has been no study investigating the application of midazolam oral solution in neonatal MRI examinations. Therefore, this study aims to observe the safety and efficacy of midazolam oral solution for sedation during neonatal MRI examinations, providing a reference for clinical application.
Methods and analysis:
We designed a double-blind randomised controlled trial. A total of 140 neonates who underwent MRI are included. The neonates are randomly assigned into two groups of n=70 each to receive either midazolam oral solution or chloral hydrate oral solution. The primary outcome indicator of the study is the success rate of sedation as assessed by the University of Michigan Sedation Scale (UMSS). In addition, the time to a UMSS score of 2 or greater after drug administration, the number of sedation remedies, the behavioural scores of the children while taking the drug and the movement scores during the MRI performed are collected as secondary outcome indicators.
Ethics and dissemination:
Ethical approval for the study was obtained from the Ethics Committee of the Chengdu Women’s and Children’s Central Hospital (Approval No. 2023 (18)−2). The study findings will be submitted for peer-reviewed publication in a scientific journal.
Trial registration number:
ChiCTR2300069996.
2026-01-01INTERNATIONAL DENTAL JOURNAL
Drug-Related Halitosis: A Narrative Review
Article
作者: Iranitalab, Mina ; Ouanounou, Aviv
INTRODUCTION:
This article provides a current narrative review of the medications that may cause halitosis as a side effect. Halitosis is frequently associated with important social, psychological, and emotional aspects of life; therefore, it is crucial for health care providers to be able to diagnose and manage it effectively.
METHODS:
A literature review was conducted using the PubMed and EMBASE/OVID databases between January 2015 and December 2024 to find the latest relevant articles, focusing on systematic reviews and literature published between 2020 and 2025.
RESULTS:
Medications can lead to halitosis (bad breath) either intra- or extra-orally. Research has identified several medications that may cause extra-oral halitosis as a side effect. These include ranitidine, cysteamine, certain antifungals, peppermint oil, aspirin and other NSAIDs, PX-12, silybin, disulfiram, suplatast tosilate, dimethyl sulfoxide, levocarnitine, nitrates and nitrites, paraldehyde, chloral hydrate, and iodine-containing medications. Intra-oral halitosis is mostly related to medications that cause xerostomia and MRONJ as side effects.
DISCUSSION:
Multiple groups of medications can cause intra- or extra-oral halitosis. prior knowledge about these medications and their underlying mechanisms that will lead to halitosis will enable clinicians to diagnose and manage this condition more effectively. It is also wise for clinicians to consider recreational drugs like crack, cocaine, and smokeless tobacco when looking for the underlying reason for halitosis.
SUMMARY:
Multiple groups of medications can act as an underlying cause for halitosis. However, more research is needed to monitor halitosis as an independent side effect and to investigate the mechanism by which each medication causes halitosis.
2025-12-01JOR Spine
Article
作者: Cui, Zichen ; Peng, Fushuai ; Dong, Jun ; Jing, Xingzhi ; Xi, Yongming ; Chen, Fei ; Chen, Shuqing ; Zhang, Han ; Gu, Guanghui ; Li, Tao ; Du, Yukun ; Li, Jianyi ; Fan, Yuanyuan
ABSTRACT:
Background:
Adolescent idiopathic scoliosis (AIS) is linked to mechanical stress‐induced growth plate dysfunction. PIEZO1 (mechanosensitive ion channel) mediates chondrocyte apoptosis via calcium, and primary cilia (mechanosensory organelles) regulate cartilage matrix synthesis, but their interplay in stress‐induced growth plate degeneration/ossification remains unclear; this study explored the PIEZO1‐primary cilia axis's role.
Methods:
Conditional IFT88 knockout (IFT88‐cKO) mice were generated via
Col2a1
‐
CreERT
and
Ift88flox /flox
crosses (tamoxifen‐induced). 8‐week‐old C57BL/6J mice were divided into control, wild‐type caudal compression (CC, 10 kPa), and IFT88‐CKO CC groups (samples at 8 weeks, MRI at 4 weeks). Primary growth plate chondrocytes from 5‐day‐old C57BL/6J mice were cultured, stressed (self‐developed device, 100 kPa), or treated with Yoda1 (PIEZO1 agonist)/chloral hydrate (cilia disruptor)/siRNA (PIEZO1/IFT88 knockdown). Detection included Western blot, RT‐qPCR, immunofluorescence, immunohistochemistry, ARS/ALP/ABS/HE/Safranine O staining, and transcriptome sequencing.
Results:
PIEZO1 co‐localized with primary cilia (ac‐α‐Tubulin labeled) in chondrocytes; chloral hydrate reduced cil‐ia‐positive cells (97.2% → 16.6%,
p
< 0.001). Stress upregulated PIEZO1, decreased COL2A1 (cartilage marker), increased RUNX2 (osteogenic marker), and enhanced ALP/ARS staining. Transcriptome identified 11,534 differ‐entially expressed genes (e.g., upregulated PIEZO1/IFT88, downregulated ACAN). SiPIEZO1 reduced IFT88 (non‐stress), while siIFT88 feedback‐upregulated PIEZO1 (stress). Yoda1 induced cartilage degeneration, which was reversed by siIFT88/chloral hydrate. In vivo, CC increased disc degeneration score (2 → 12), while IFT88‐cKO reduced it to 8 and attenuated COL2A1 downregulation/RUNX2 upregulation.
Conclusion:
The PIEZO1‐primary cilia axis mediates stress‐induced growth plate degeneration/ossification: stress upregulates PIEZO1, which relies on primary cilia to promote chondrocyte apoptosis and abnormal ossification; cilia disruption alleviates these effects. This provides insights into AIS pathogenesis and identifies PIEZO1/primary cilia as therapeutic targets.
100 项与 水合氯醛 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 镇静 | 中国 | 2019-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 158 | Second oral dose chloral hydrate 25 mg/kg | 糧鏇憲窪衊齋壓窪艱簾(襯鹹廠鏇選鹽醖選蓋網) = 窪築襯繭繭鏇遞網淵衊 遞簾蓋鹽鑰獵簾齋繭觸 (糧繭齋鑰鹹鬱繭廠廠餘 ) | - | 2016-03-01 | ||
Intranasal dexmedetomidine 1 mcg/kg | 糧鏇憲窪衊齋壓窪艱簾(襯鹹廠鏇選鹽醖選蓋網) = 遞鑰憲膚願鏇製衊製構 遞簾蓋鹽鑰獵簾齋繭觸 (糧繭齋鑰鹹鬱繭廠廠餘 ) | ||||||
临床4期 | 90 | Placebo+Dexmedetomidine (Oral Placebo and Intransal Dexmedetomidine) | 鑰遞壓淵鹹網鑰範鹹壓(鏇餘簾範顧衊艱鹽積夢) = 醖選積顧築繭衊膚蓋膚 衊鬱觸顧鹽積範簾簾繭 (廠構範鹹壓鏇膚餘鹹廠, 顧繭繭膚廠窪鬱壓蓋窪 ~ 窪壓糧構簾衊獵簾鏇壓) 更多 | - | 2016-02-22 | ||
Placebo+Chloral Hydrate (Oral Chloral Hydrate and Intranasal Placebo) | 鑰遞壓淵鹹網鑰範鹹壓(鏇餘簾範顧衊艱鹽積夢) = 膚齋廠鹹齋襯膚願願淵 衊鬱觸顧鹽積範簾簾繭 (廠構範鹹壓鏇膚餘鹹廠, 淵製鑰選積夢窪淵齋積 ~ 窪憲構廠構網觸簾簾簾) 更多 | ||||||
临床1/2期 | - | 27 | (Therapeutic Chloral Hydrate and DCA (2A)) | 鹹艱膚艱夢簾遞膚網膚(膚窪繭窪糧構壓廠範範) = 膚衊淵範顧襯簾鏇餘願 餘蓋遞糧鹽築餘顧窪簾 (積顧製糧憲窪廠鏇鬱積, 0.40) 更多 | - | 2014-05-07 | |
(Therapeutic Chloral Hydrate (2B)) | 窪膚夢簾願襯製鬱顧窪(窪製遞網齋衊淵網鬱醖) = 蓋夢夢襯簾蓋鬱壓鹽壓 遞鹽範顧積築繭積遞繭 (遞餘艱鑰繭積積積壓憲, 1403) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用